DEFC14A: Kellner Group Seeks to Overhaul AIM ImmunoTech Board Amidst Stock Price Plunge and Governance Concerns

The Kellner Group, holding approximately 5.04% of AIM ImmunoTech's shares, is soliciting proxies to elect its four nominees to the board, citing significant concerns over the company's performance and governance.

Summary

• The Kellner Group, led by Ted D. Kellner, is seeking to elect its nominees to AIM ImmunoTech's Board of Directors at the upcoming Annual Meeting on December 17, 2024.
• The Kellner Group believes significant changes are needed due to a massive decline in AIM's stock price (over 99% since 2016), irresponsible financial management, inadequate clinical progress, and wasteful entrenchment efforts by the current board.
• The Kellner Group Nominees are Ted D. Kellner, Todd Deutsch, Robert L. Chioini, and Paul W. Sweeney, who collectively bring extensive business, financial, clinical trial, life science, and governance experience.
• The Kellner Group beneficially owns 3,211,100 shares of Common Stock, representing approximately 5.04% of the outstanding shares as of October 28, 2024.
• The Kellner Group intends to vote its shares FOR its nominees, FOR the ratification of the independent registered public accounting firm, and AGAINST the advisory vote approving executive compensation.
• The proxy statement highlights concerns about the incumbent board's entrenchment efforts, including the adoption of amended bylaws that were later deemed a breach of fiduciary duty by the Delaware Supreme Court.
• The Kellner Group estimates that the Company has spent over $15.0 million in the past two years in bad faith entrenchment efforts.
• The Kellner Group criticizes the incumbent board's financial management, citing a precarious cash position and recent dilutive financing transactions.
• The Kellner Group also raises concerns about inadequate clinical and commercial progress with Ampligen, AIM's lead drug candidate, despite decades of development.
• The Kellner Group intends to enhance the value of AIM by rebuilding investor trust, conducting a review of management, and advancing clinical trial efforts with respect to the most promising indications for Ampligen.

Sentiment

Score: 2

Explanation: The document expresses a highly negative sentiment towards the current management and board of AIM ImmunoTech, citing significant concerns over the company's performance, governance, and financial management. The Kellner Group clearly believes that drastic changes are needed to improve the company's prospects.

Positives

• The Kellner Group Nominees bring a wealth of business, financial, clinical trial, life science and governance experience.
• The Kellner Group intends to rebuild investor trust by clearly communicating with them.
• The Kellner Group intends to define and execute a focused clinical trial strategy and responsibly use corporate assets to advance that strategy.
• The Kellner Group intends to implement effective corporate governance and improve communications with stockholders.
• The Kellner Group intends to share its strategy with potential institutional health care investors.

Negatives

• AIM's stock price has declined by over 99% since Mr. Equels became CEO and Mr. Equels, Dr. Mitchell and Mr. Appelrouth assumed control of the Board.
• The Delaware Supreme Court ruled that the incumbent board breached its fiduciary duty of loyalty in adopting amended bylaws.
• The Kellner Group estimates that the Company has spent over $15.0 million in the past two years in bad faith entrenchment efforts.
• AIM's financial condition is precarious, with effective liquidity of less than $5.0 million as of June 30, 2024.
• AIM has engaged in highly dilutive financing alternatives, including a usurious two-year loan and equity line agreements with entities controlled by individuals with a history of securities law violations.
• AIM has failed to generate meaningful regulatory approval or sales for Ampligen despite decades of clinical development.
• General and administrative spending has exceeded research and development spending in recent years.
• The incumbent board has been criticized for excessive compensation despite poor performance.

Risks

• The Company's precarious financial condition may require further dilutive financing.
• Failure to achieve regulatory approval for Ampligen could significantly impact the Company's future prospects.
• Continued entrenchment efforts by the incumbent board could further alienate stockholders and potential investors.
• The outcome of ongoing litigation, including the Florida Section 13(d) Action and the Jorgl Delaware Action, could result in additional expenses.
• The Company's ability to attract long-term institutional investors is uncertain.

Future Outlook

The Kellner Group intends to enhance the value of AIM by rebuilding investor trust, conducting a review of management, and advancing clinical trial efforts with respect to the most promising indications for Ampligen.

Management Comments

• We believe AIM will only have a chance to be successful when it has a new Board that can serve as a respected steward of investor capital and earn the trust of existing and potential stockholders.
• We believe the past actions of the incumbent Board, highlighted by the ruling of the Delaware Supreme Court that the amended bylaws adopted by Mr. Equels, Dr. Mitchell and Mr. Appelrouth in 2023 were the product of an improper motive and purpose, which constitutes a breach of the duty of loyalty, are disqualifying in this respect.
• We intend to enhance the value of AIM by: Rebuilding the trust of current and new investors by clearly communicating with them.
• We intend to define and execute a focused clinical trial strategy and responsibly use corporate assets to advance that strategy, while simultaneously implementing effective corporate governance and improving communications with stockholders and sharing our strategy with potential institutional health care investors.
• We believe it is necessary to attract long-term institutional investors so that AIM can raise the necessary capital to support its efforts without destroying stockholder value.
• The Kellner Group Nominees, if elected, intend to conduct a review to gather all necessary information and meet with management and key personnel before making any decisions and would ultimately do what they consider to be in the best interests of the Company and its stockholders after conducting such review.

Industry Context

The proxy statement highlights the underperformance of AIM ImmunoTech compared to the Russell 2000 Index and the Nasdaq Biotechnology Index, suggesting that the company's struggles are not simply due to broader market conditions but rather company-specific issues.

Comparison to Industry Standards

• The document does not provide specific comparisons to comparable companies or projects in the pharmaceutical or biotechnology industry.
• However, it implies that AIM ImmunoTech's clinical and commercial progress is lagging behind industry standards, given the decades of development without meaningful regulatory approval or sales for Ampligen.
• The document also suggests that AIM ImmunoTech's corporate governance practices are below industry standards, citing the Delaware Supreme Court's ruling that the incumbent board breached its fiduciary duty of loyalty.

Legal Proceedings

• The Florida federal court sanctioned AIM and its counsel for certain actions taken in the Florida Section 13(d) Action.
• The Delaware Supreme Court ruled that the incumbent board breached its fiduciary duty of loyalty in adopting amended bylaws.
• Mr. Kellner has submitted a Section 220 Demand to inspect certain books and records of the Company.

Stakeholder Impact

• The Kellner Group believes that significant changes to the Board are necessary to ensure that the Company is overseen in a manner consistent with its stockholders best interests.
• The Kellner Group intends to rebuild the trust of current and new investors by clearly communicating with them.
• The Kellner Group intends to conduct a review of management and key personnel to ensure that the Company has the right resources in place to execute on important strategic initiatives and create stockholder value.

Next Steps

• Stockholders are urged to vote FOR the Kellner Group Nominees on the GOLD proxy card.
• The Annual Meeting of Stockholders will be held on December 17, 2024.
• The Kellner Group intends to seek reimbursement from the Company of all expenses incurred in connection with this solicitation.

Key Dates

Keywords

proxy solicitation, board of directors, corporate governance, AIM ImmunoTech, Kellner Group, Ampligen, stock price, fiduciary duty, entrenchment, executive compensation